skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In-depth news and analysis

Generics_Bulletin2

How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.

How it works

A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.

Analysis and opinion covers key topic areas such as:

  • Regulatory and compliance changes
  • Legal and legislations advances
  • Competitive developments
  • Merger and acquisition activities
  • New product launches
  • Marketing challenges
  • Advertising strategies, and more.

What's included

Pharma Intelligence: latest

  • Generics Bulletin

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

  • Generics Bulletin

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic Biosimilars

  • Generics Bulletin

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion-Will-Trial-COVID-19-Antiviral-From-July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus Vaccines

  • Generics Bulletin

    Australian Bodies Set Out Joint Position On Coronavirus

    Australian-Bodies-Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

  • Generics Bulletin

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger logo

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

  • Generics Bulletin

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

    Topic Coronavirus

  • Generics Bulletin

    Celltrion Makes Progress On Coronavirus Treatment

    Coronavirus_Elbow_pump

    Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

    Topic Coronavirus

  • Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Generics Bulletin

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    Donald Trump

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

  • In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...

    Coronavirus: Keep up to date with Breaking News and Insight

    Coronavirus_Cover

    Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.

    Topic Coronavirus

  • Generics Bulletin

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Corona_Invivo

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

  • Generics Bulletin

    Celltrion Pledges Efforts on Coronavirus Antibody And Kit

    Coronavirus

    Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

    Topic Coronavirus

  • Generics Bulletin

    Green Lanes Will Help EU Fight Coronavirus

    Coronavirus Europe

    Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

    Topic Coronavirus

  • Generics Bulletin

    European Coronavirus Planning Requires ‘Structured Dialog’

    Coronavirus

    European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

    Topic Coronavirus

  • Generics Bulletin

    Sun Finds US ‘Challenging’

    Flags_USA_India

    Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

    Topic Deal trends

Meet the team

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market Intelligence

+22 year(s) experience

Consultant

Duncan Emerton

Consultant, Director Pharma Consulting

UK

Duncan Emerton

Duncan specializes in

  • Commercial Strategy
  • Biosimilars
  • Generics

+20 year(s) experience

Editor

Andrea Charles

Editor, Editor, Custom Content

UK

Andrea Charles

Andrea specializes in

  • Biosimilars
  • Biotech
  • Commercial Strategy
  • Generics
  • Clinical Trials

+17 year(s) experience

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: